» Articles » PMID: 36699973

Determinants and Neonatal Outcomes of Preeclampsia Among Women Living with and Without HIV at a Tertiary Hospital in Zambia: a Review of Medical Records

Overview
Journal Pan Afr Med J
Date 2023 Jan 26
PMID 36699973
Authors
Affiliations
Soon will be listed here.
Abstract

Introduction: pre-eclampsia, a pregnancy-specific condition that occurs after 20 weeks of gestation, is a significant public health problem. In the extant literature, there are still conflicting reports on whether Human immunodeficiency virus (HIV) infection and antiretroviral therapy (ART) affect preeclampsia rates. We, therefore, explored the determinants and neonatal outcomes of preeclampsia among pregnant women living with and without HIV.

Methods: we reviewed delivery registers and neonatal files from the 1 January 2018, to 30 of September 2019 for women who delivered at Women and Newborn Hospital. The logistic regression model estimated the odds of preeclampsia and described the neonatal outcomes.

Results: the prevalence of preeclampsia was 7.7% (95% confidence intervals: 6.8 to 8.7). On ART, pregnant women with HIV infection were less likely to develop preeclampsia than those without HIV infection (aOR=0.50; 95% CI: 0.32 to 0.80). However, neonates born to women with preeclampsia were more likely to be admitted to kangaroo mother care than neonates born to normotensive women, regardless of the HIV-exposure status.

Conclusion: overall, the prevalence of preeclampsia was 7.7%, but it was less common among HIV-infected pregnant women receiving ART. Neonates born from women with preeclampsia are at increased risk of adverse outcomes, including admission to kangaroo mother care. These findings underscore the need for healthcare workers to direct their efforts on early diagnosis and detection of preeclampsia in pregnant women to prevent poor outcomes.

Citing Articles

Preeclampsia: Etiology, Pathophysiology, Risk Factors, Impact and Prevention: A Narrative Review.

Mustary M, Ansariadi , Syam A, Riskiyani S, Erika K, Moedjiono A Iran J Public Health. 2024; 53(11):2392-2403.

PMID: 39619908 PMC: 11607152. DOI: 10.18502/ijph.v53i11.16941.


High sensitivity C-reactive protein in pre-eclamptic women living with HIV at a tertiary hospital in Zambia: a preliminary study.

Kabaya Z, Omar R, Kumwenda A, Muyangwa-Semenova M, Mukosha M Pan Afr Med J. 2024; 48:136.

PMID: 39554261 PMC: 11567906. DOI: 10.11604/pamj.2024.48.136.42683.


Persistent hypertension among postpartum women with comorbid HIV and preeclampsia in Zambia.

Mukosha M, Hatcher A, Lubeya M, Maposa I, Chi B, Mutale W PLoS One. 2024; 19(9):e0309915.

PMID: 39231156 PMC: 11373822. DOI: 10.1371/journal.pone.0309915.

References
1.
Haeri S, Shauer M, Dale M, Leslie J, Baker A, Saddlemire S . Obstetric and newborn infant outcomes in human immunodeficiency virus-infected women who receive highly active antiretroviral therapy. Am J Obstet Gynecol. 2009; 201(3):315.e1-5. DOI: 10.1016/j.ajog.2009.06.017. View

2.
Belay A, Wudad T . Prevalence and associated factors of pre-eclampsia among pregnant women attending anti-natal care at Mettu Karl referal hospital, Ethiopia: cross-sectional study. Clin Hypertens. 2019; 25:14. PMC: 6600877. DOI: 10.1186/s40885-019-0120-1. View

3.
Pillay P, Moodley K, Vatish M, Moodley J, Duarte R, Mackraj I . Exosomal Th1/Th2 cytokines in preeclampsia and HIV-positive preeclamptic women on highly active anti-retroviral therapy. Cytokine. 2019; 125:154795. DOI: 10.1016/j.cyto.2019.154795. View

4.
Duley L . The global impact of pre-eclampsia and eclampsia. Semin Perinatol. 2009; 33(3):130-7. DOI: 10.1053/j.semperi.2009.02.010. View

5.
Kalumba V, Moodley J, Naidoo T . Is the prevalence of pre-eclampsia affected by HIV/AIDS? A retrospective case-control study. Cardiovasc J Afr. 2013; 24(2):24-7. PMC: 3734876. DOI: 10.5830/CVJA-2012-078. View